Accessibility Screen-Reader Guide, Feedback, and Issue Reporting
timothy sykes logo

Stock News

Tempus AI Reveals Game-Changing Diagnostics

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 2/13/2025, 2:33 pm ET 6 min read
Tempus AI Reveals Game-Changing Diagnostics Thumbnail

Tempus AI Inc.’s shares soar as investors grow optimistic about innovative product developments and increased collaboration in the artificial intelligence space, driving a notable uptrend. On Thursday, Tempus AI Inc.’s stocks have been trading up by 14.92 percent.

Impactful Developments for Tempus AI

  • Tempus AI’s new diagnostic device, xT CDx, has now received FDA approval and is available across the nation, promising comprehensive profiling for solid tumors.

Candlestick Chart

Live Update At 14:32:40 EST: On Thursday, February 13, 2025 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 14.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • A recent acquisition, Ambry Genetics, positions Tempus AI to integrate genetic testing with precision medicine, pushing forward patient care advancements.

  • A strategic share repurchase strategy has been exemplified by the Templeton Emerging Markets Investment Trust, acquiring its own shares to bolster shareholder value.

  • The Templeton Emerging Markets Investment Trust finalized a substantial multi-currency revolving loan, furthering its financial flexibility and strategic expansion capacity.

Tempus AI’s Financial Health and Potential

As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” This principle is crucial for every trader, especially when navigating the volatile and unpredictable nature of the market. By focusing on protecting your resources and maintaining a long-term perspective, you ensure that you’re always in a position to take advantage of the next opportunity. The key to success in trading lies in understanding that not every trade will be profitable, but each one offers valuable lessons that contribute to lasting success.

Tempus AI has been busy, showing a financial roadmap that’s anything but ordinary. Their latest actions hint at a plan well beyond today’s rapidly advancing healthcare technologies. Beginning with their bold acquisition of Ambry Genetics, the company merges its AI capabilities with genetic insights—a pairing that could transform patient experiences.

In assessing Tempus AI’s financial outcomes, one spots a landscape speckled with contrasts. On the one hand, with a negative EBITDA and a pretax profit margin of -42.5%, challenges aren’t foreign to this trailblazer. Yet, their revenue streams promise something more ambitious, a burgeoning empire of data-driven healthcare solutions.

More Breaking News

The market seems to respond to adventure, and this trend is evident here. Tempus AI’s stock prices show a story of calculated risk turning into potential ripened reward. The patient interplay between share buybacks and stock price variability paints a telling tale about market opportunities that the company is keen to exploit.

News Analysis: Getting Behind Stock Fluctuations

Tempus AI’s FDA approval for its xT CDx device is a milestone of notable significance. It’s not just another feather in the company’s cap—it’s a vanguard step forward in cancer diagnosis. With this groundbreaking diagnostic tool, clinicians can now access a wealth of genetic data to better thwart tumors. This achievement could cultivate an image that extends far, amplifying both interest and investment in Tempus AI. Stocks soared in light of these developments, their allure deepening among investors.

The enthusiasm around their acquisition of Ambry Genetics speaks for itself. Genetic testing represents a pivot towards more bespoke healthcare—a realm crucial for future advancements. This acquisition sends ripples through the investment community, suggesting that Tempus AI isn’t just standing still but racing towards a forward-thinking horizon.

There’s the affair with share purchases by Templeton Emerging Markets Investment Trust that caught many market observers’ eyes. This strategic repurchase not only aims to enhance stakeholder confidence but potentially boosts the company’s valuation. It’s the kind of maneuver that pronounces trust in a company’s future and underpins expectations of long-term growth.

The Market’s Verdict

The flurrying whirl of business maneuvers executed by Tempus AI is much akin to a chess match in a grander theater of healthcare innovation. Their ability to grasp opportunities and make decisive plays tells of an enterprise that’s not engaged in negligible follies but aiming at the very zenith of medical scope.

Traders, whether tentative or bold, perceive this as a prime moment, with an urge to recalibrate their portfolios. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” Tempus AI’s conjuring of new pathways in patient care heralds promising avenues, and everyone’s watching to see which echoes reverberate farthest and longest.

Even so, it’s essential for traders to remember the dance between potential and risk in this volatile yet promising industry. Venturing into Tempus AI might feel like charting new waters, but for those ready to steer, the horizon probably shimmers with the nascent glow of discovery and success.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM
notification icon
Subscribe to receive notifications